Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Lyumjev ® ▼ (insulin lispro)
Lyumjev® ▼ (insulin lispro): Treprostinil Dose in the Commercial Formulation
The formulation contains 10 ng of treprostinil per unit of insulin lispro (100 units/mL formulation).
The commercial formulation of Lyumjev contains 10 ng of treprostinil per unit of insulin lispro in a 100 unit/mL formulation.1
treprostinil = Remodulin® (treprostinil) injection
URLi = ultra rapid lispro
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: July 19, 2019